Cargando…
The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete patholo...
Autores principales: | Pop, Lucian, Suciu, Ioan Dumitru, Ionescu, Olivia, Ionescu, Paris, Toader, Oana Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993292/ https://www.ncbi.nlm.nih.gov/pubmed/32025249 http://dx.doi.org/10.25122/jml-2019-0115 |
Ejemplares similares
-
Tuberculosis in pregnancy
por: Pop, Lucian Gheorghe, et al.
Publicado: (2021) -
The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature
por: Pop, Lucian, et al.
Publicado: (2021) -
Non-Invasive Prenatal Testing beyond Trisomies
por: Suciu, Ioan Dumitru, et al.
Publicado: (2019) -
Fibular hemimelia
por: Georgescu, Tiberiu, et al.
Publicado: (2022) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)